Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma: First experiences of the German radiotherapy quality control panel in the SIOP PNET5 MB trial

Standard

Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma: First experiences of the German radiotherapy quality control panel in the SIOP PNET5 MB trial. / Dietzsch, Stefan; Braesigk, Annett; Seidel, Clemens; Remmele, Julia; Kitzing, Ralf; Schlender, Tina; Mynarek, Martin; Geismar, Dirk; Jablonska, Karolina; Schwarz, Rudolf; Pazos, Montserrat; Walser, Marc; Frick, Silke; Gurtner, Kristin; Matuschek, Christiane; Harrabi, Semi Ben; Glück, Albrecht; Lewitzki, Victor; Dieckmann, Karin; Benesch, Martin; Gerber, Nicolas U; Rutkowski, Stefan; Timmermann, Beate; Kortmann, Rolf-Dieter.

In: STRAHLENTHER ONKOL, Vol. 197, No. 8, 08.2021, p. 674-682.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Dietzsch, S, Braesigk, A, Seidel, C, Remmele, J, Kitzing, R, Schlender, T, Mynarek, M, Geismar, D, Jablonska, K, Schwarz, R, Pazos, M, Walser, M, Frick, S, Gurtner, K, Matuschek, C, Harrabi, SB, Glück, A, Lewitzki, V, Dieckmann, K, Benesch, M, Gerber, NU, Rutkowski, S, Timmermann, B & Kortmann, R-D 2021, 'Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma: First experiences of the German radiotherapy quality control panel in the SIOP PNET5 MB trial', STRAHLENTHER ONKOL, vol. 197, no. 8, pp. 674-682. https://doi.org/10.1007/s00066-020-01707-8

APA

Dietzsch, S., Braesigk, A., Seidel, C., Remmele, J., Kitzing, R., Schlender, T., Mynarek, M., Geismar, D., Jablonska, K., Schwarz, R., Pazos, M., Walser, M., Frick, S., Gurtner, K., Matuschek, C., Harrabi, S. B., Glück, A., Lewitzki, V., Dieckmann, K., ... Kortmann, R-D. (2021). Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma: First experiences of the German radiotherapy quality control panel in the SIOP PNET5 MB trial. STRAHLENTHER ONKOL, 197(8), 674-682. https://doi.org/10.1007/s00066-020-01707-8

Vancouver

Bibtex

@article{ed07970492c748ce8af0d72fcc57fb53,
title = "Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma: First experiences of the German radiotherapy quality control panel in the SIOP PNET5 MB trial",
abstract = "PURPOSE: Several studies have demonstrated the negative impact of radiotherapy protocol deviations on tumor control in medulloblastoma. In the SIOP PNET5 MB trial, a pretreatment radiotherapy quality control (RT-QC) program was introduced. A first analysis for patients enrolled in Germany, Switzerland and Austria with focus on types of deviations in the initial plan proposals and review criteria for modern radiation technologies was performed.METHODS AND PATIENTS: Sixty-nine craniospinal irradiation (CSI) plans were available for detailed analyses. RT-QC was performed according to protocol definitions on dose uniformity. Because of the lack of definitions for high-precision 3D conformal radiotherapy within the protocol, additional criteria for RT-QC on delineation and coverage of clinical target volume (CTV) and planning target volume (PTV) were defined and evaluated.RESULTS: Target volume (CTV/PTV) deviations occurred in 49.3% of initial CSI plan proposals (33.3% minor, 15.9% major). Dose uniformity deviations were less frequent (43.5%). Modification of the RT plan was recommended in 43.5% of CSI plans. Unacceptable RT plans were predominantly related to incorrect target delineation rather than dose uniformity. Unacceptable plans were negatively correlated to the number of enrolled patients per institution with a cutoff of 5 patients (p = 0.001).CONCLUSION: This prospective pretreatment individual case review study revealed a high rate of deviations and emphasizes the strong need of pretreatment RT-QC in clinical trials for medulloblastoma. Furthermore, the experiences point out the necessity of new RT-QC criteria for high-precision CSI techniques.",
author = "Stefan Dietzsch and Annett Braesigk and Clemens Seidel and Julia Remmele and Ralf Kitzing and Tina Schlender and Martin Mynarek and Dirk Geismar and Karolina Jablonska and Rudolf Schwarz and Montserrat Pazos and Marc Walser and Silke Frick and Kristin Gurtner and Christiane Matuschek and Harrabi, {Semi Ben} and Albrecht Gl{\"u}ck and Victor Lewitzki and Karin Dieckmann and Martin Benesch and Gerber, {Nicolas U} and Stefan Rutkowski and Beate Timmermann and Rolf-Dieter Kortmann",
note = "{\textcopyright} 2020. The Author(s).",
year = "2021",
month = aug,
doi = "10.1007/s00066-020-01707-8",
language = "English",
volume = "197",
pages = "674--682",
journal = "STRAHLENTHER ONKOL",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "8",

}

RIS

TY - JOUR

T1 - Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma: First experiences of the German radiotherapy quality control panel in the SIOP PNET5 MB trial

AU - Dietzsch, Stefan

AU - Braesigk, Annett

AU - Seidel, Clemens

AU - Remmele, Julia

AU - Kitzing, Ralf

AU - Schlender, Tina

AU - Mynarek, Martin

AU - Geismar, Dirk

AU - Jablonska, Karolina

AU - Schwarz, Rudolf

AU - Pazos, Montserrat

AU - Walser, Marc

AU - Frick, Silke

AU - Gurtner, Kristin

AU - Matuschek, Christiane

AU - Harrabi, Semi Ben

AU - Glück, Albrecht

AU - Lewitzki, Victor

AU - Dieckmann, Karin

AU - Benesch, Martin

AU - Gerber, Nicolas U

AU - Rutkowski, Stefan

AU - Timmermann, Beate

AU - Kortmann, Rolf-Dieter

N1 - © 2020. The Author(s).

PY - 2021/8

Y1 - 2021/8

N2 - PURPOSE: Several studies have demonstrated the negative impact of radiotherapy protocol deviations on tumor control in medulloblastoma. In the SIOP PNET5 MB trial, a pretreatment radiotherapy quality control (RT-QC) program was introduced. A first analysis for patients enrolled in Germany, Switzerland and Austria with focus on types of deviations in the initial plan proposals and review criteria for modern radiation technologies was performed.METHODS AND PATIENTS: Sixty-nine craniospinal irradiation (CSI) plans were available for detailed analyses. RT-QC was performed according to protocol definitions on dose uniformity. Because of the lack of definitions for high-precision 3D conformal radiotherapy within the protocol, additional criteria for RT-QC on delineation and coverage of clinical target volume (CTV) and planning target volume (PTV) were defined and evaluated.RESULTS: Target volume (CTV/PTV) deviations occurred in 49.3% of initial CSI plan proposals (33.3% minor, 15.9% major). Dose uniformity deviations were less frequent (43.5%). Modification of the RT plan was recommended in 43.5% of CSI plans. Unacceptable RT plans were predominantly related to incorrect target delineation rather than dose uniformity. Unacceptable plans were negatively correlated to the number of enrolled patients per institution with a cutoff of 5 patients (p = 0.001).CONCLUSION: This prospective pretreatment individual case review study revealed a high rate of deviations and emphasizes the strong need of pretreatment RT-QC in clinical trials for medulloblastoma. Furthermore, the experiences point out the necessity of new RT-QC criteria for high-precision CSI techniques.

AB - PURPOSE: Several studies have demonstrated the negative impact of radiotherapy protocol deviations on tumor control in medulloblastoma. In the SIOP PNET5 MB trial, a pretreatment radiotherapy quality control (RT-QC) program was introduced. A first analysis for patients enrolled in Germany, Switzerland and Austria with focus on types of deviations in the initial plan proposals and review criteria for modern radiation technologies was performed.METHODS AND PATIENTS: Sixty-nine craniospinal irradiation (CSI) plans were available for detailed analyses. RT-QC was performed according to protocol definitions on dose uniformity. Because of the lack of definitions for high-precision 3D conformal radiotherapy within the protocol, additional criteria for RT-QC on delineation and coverage of clinical target volume (CTV) and planning target volume (PTV) were defined and evaluated.RESULTS: Target volume (CTV/PTV) deviations occurred in 49.3% of initial CSI plan proposals (33.3% minor, 15.9% major). Dose uniformity deviations were less frequent (43.5%). Modification of the RT plan was recommended in 43.5% of CSI plans. Unacceptable RT plans were predominantly related to incorrect target delineation rather than dose uniformity. Unacceptable plans were negatively correlated to the number of enrolled patients per institution with a cutoff of 5 patients (p = 0.001).CONCLUSION: This prospective pretreatment individual case review study revealed a high rate of deviations and emphasizes the strong need of pretreatment RT-QC in clinical trials for medulloblastoma. Furthermore, the experiences point out the necessity of new RT-QC criteria for high-precision CSI techniques.

U2 - 10.1007/s00066-020-01707-8

DO - 10.1007/s00066-020-01707-8

M3 - SCORING: Journal article

C2 - 33226469

VL - 197

SP - 674

EP - 682

JO - STRAHLENTHER ONKOL

JF - STRAHLENTHER ONKOL

SN - 0179-7158

IS - 8

ER -